Mankind Pharma Ltd. · NSE:MANKIND
Mankind Pharma — Merger or Acquisition (July 2024)
22 slides from Mankind Pharma's merger presentation, Jul 25, 2024
Slide 1: Exchange filing cover letter: Investor Presentation
Date: July 25, 2024 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Script Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Investor Presentation Pursuant to Regulat
Slide 2: Investor Presentation July 2024
Cn Mankind> @BSV Serving Life Building High Entry Barrier Complex Portfolio with Leadership in Women’s Health and Infertility Investor Presentation July 2024
Slide 3: Forward-looking statements disclaimer
Some statements in this release regarding our future growth prospects are forward-looking and subject to various risks, uncertainties, and assumptions that may cause actual results to differ significantly from those anticipated. Key factors that could lead to such differences include, among others,
Slide 4: Transaction Overview
_} » Transaction Overview BSV Overview Transaction Details Transaction Funding Impact on Financials Transaction Timelines ig Mankindil> Serving Life BSV is a Leading Branded Specialty Pharma Platform in Women’s Health and Critical care with huge opportunity in both India and International Markets BS
Slide 5: BSV Overview
Big Domestic Brands¹ World’s 1st & Only INR 100cr+: 1 Anti Rho(D) Recombinant Antibody Fast Growing & Comprehensive INR 50-100cr: 3 India’s 1st Fertility Portfolio INR 25-50cr: 8 Anti thymocyte Ig, r-FSH, High Pure HMG and r-HCG 76% | 55% 28% Women’s Health sales in 21% Adj. EBITDA Margin³ Domestic
Slide 6: High Entry Barrier Portfolio
High Entry R&D Complementary EBITDA Margin Net debt/ Unlock Barrier Specialty Tech Portfolio Accretive EBITDA Synergies Portfolio Platform <2x by FY26 5
Slide 7: FY24 pro-forma combined financials
FY24 Pro-forma company INR cr Revenue 10,335 1,723 12,058 (y-o-y Growth) +18% +20% International International 8% 13% International Revenue Mix % 46% Domestic 54% Domestic Domestic 87% 92% Brands (>INR 50cr) 40 10 50 EBITDA 2,550 4891 3,039 EBITDA Margin % 24.7% 28.4% 25.2% Note: 6 1. EBITDA for BSV
Slide 8: BSV key strengths
High Entry Barrier ▪ Only innovator in the world to develop patented recombinant Anti-D Business ▪ Complex portfolio & biologics need 5-10 years R&D to develop Big Opportunity in ▪ Rising infertility driven by lifestyle changes, delayed parenthood, chronic diseases Fertility Drugs ▪ Presence / pipel
Slide 9: Established R&D platform and manufacturing capabilities
▪ Recombinant tech/niche biologics: Anti Rho(D), rFSH; HCG/rHCG, HMG; IVIG Established ▪ Immunoglobulin (IgG): Equine Anti-thymocyte IgG, Snake Venom Antiserum, Equine Rabies IgG R&D platform ▪ Complex Delivery Systems: Liposomal Amphotericin B; Leuprolide Microsphere Tech Complex ▪ Ambernath facili
Slide 10: Recombinant Anti-D
▪ In India, 5-7% eligible mothers are Rh-negative ▪ 80L – 1cr mothers Key Differentiators ▪ Lack of preventive measures can cause ▪ Brain damage ▪ World’s FIRST and ONLY recombinant for Anti ▪ Jaundice in new borns RhoD ▪ Indication: For Rh-negative eligible mothers (Rh-positive fetus) ▪ Patent in N
Slide 11: Anti-thymocyte globulin and rFSH
▪ Only ATG in India ▪ First biosimilar of rFSH in India (Best-in-Class tech) ▪ Indication: Rare disease - Aplastic Anemia ▪ Indication: Infertility in women for ovulation stimulation ▪ Bone marrow does not produce enough blood cells due to ▪ Strong distribution capability with 90-100% reach in unkno
Slide 12: Fertility market tailwinds and penetration headroom
Penetration Bound to Increase Driven by Strong Macro Tailwinds - Improved Awareness, Accessibility, Affordability of IVF Treatments ▪1 Decline in fertility rates driven by lifestyle changes, ▪3 Increasing affordability and awareness with delayed parenthood, prevalence of rising incomes higher female
Slide 13: Comprehensive fertility drugs portfolio versus peers
Fertility Pregnancy & Post-Pregnancy Full Coverage (Medicines/drugs used as a part of Assisted reproductive (Medicines used for supporting pregnancy, post pregnancy of WH technologies (IVF/IUI) cycles) and menopause) Offerings HMG (Humog), FSH (Foligraf) Galactagogues (Lactare), Calcium combination
Slide 14: Indian gynaecology market position and coverage
#1 Player in Indian Gynaecology Market (INR 10,858 cr) Complementary Therapies2 Market Select Therapies Mankind BSV 13% 9% 7% 6% 5% 4% 4% 6% 1 Share % Women Health Rx PPPP PP Women Health Specialty PPP PPPP Critical Care P PP Fertility P PPP Animal Bites PP 1 Coverage Expansion Mankind BSV Field-for
Slide 15: BSV Market Share – Domestic (FY24)
BSV Market Share – Domestic (FY24) Women Health Fertility Critical Care/Ig Anti-D / Rhoclone Thymogam ASVS Hucog Humog Luprodex Foligraf Source: Market data and market share data as per Third Party Report 14 Note: Sales in INR Cr for FY24
Slide 16: International business
Revenues $77m International Business Revenue1 (FY21-24 Revenue CAGR - 25% in cc terms) Geographic 2 Home Markets Established – • ASEAN • MENA Spread Philippines and Malaysia • LATAM • RCIS Brands and Focused presence across Increasing focus on fertility TA Focus 7 brand families S&M and 260+ FF stre
Slide 17: Highly sophisticated technology platforms
Recombinant Tech and Highly Sophisticated Tech Niche Biologics Complex Delivery Systems Immunoglobulins Platforms… Unique products in WH & fertility through “Selective therapy specific” Immunoglobulins through animal platform for recombinant platform & chromatographic NDDS products critical care pro
Slide 18: Manufacturing facilities and expansion potential
Best in class injectable facility in Ambernath with sufficient capacity Upcoming Genome Valley 1 3 Expansion Potential Inspected by EUGMP and Capabilities across accredited by major 5 dedicated injectable Recombinant, Equine, regulatory agencies lines producing for Indian Hormonal and Complex includ
Slide 19: Revenue and cost synergies
Revenue Synergies Cost Synergies ▪ Leverage Mankind’s extensive geographical and doctor ▪ Improve BSV’s MR productivity by leveraging Mankind’s operational excellence coverage ▪ Potential OTX shift ▪ Potential shift of outsourced manufacturing for ▪ BSV’s comprehensive Fertility portfolio to ensure
Slide 20: Summary: high entry barrier portfolio
High entry barrier portfolio with Specialty R&D Tech platforms across - Recombinants, Niche Biologics, Novel Delivery and Immunoglobulins 19
Slide 21: Investor call details
Date 26 July, 2024 Time 04:00 PM IST Dial – In Details Universal Access Numbers +91 22 6280 1102 / +91 22 7115 8003 USA : 18667462133 UK : 08081011573 International Toll-Free Numbers Singapore : 8001012045 Hong Kong : 800964448 https://services.choruscall.in/DiamondPassRegistration/register?confirma
Slide 22: Thank You
Thank You